Expression of recombinant HLA-DR2 molecules. Replacement of the hydrophobic transmembrane region by a leucine zipper dimerization motif allows the assembly and secretion of soluble DR alpha beta heterodimers.
about
Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting proteinStructural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac diseaseMajor Histocompatibility Complex Class II Dextramers: New Tools for the Detection of antigen-Specific, CD4 T Cells in Basic and Clinical ResearchEx vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramersCrystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsyCrystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic proteinHigh-throughput engineering and analysis of peptide binding to class II MHCDevelopment and use of multimeric major histocompatibility complex molecules.Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.Cell surface display of functional human MHC class II proteins: yeast display versus insect cell displayRole of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of "Humanized" Multiple Sclerosis-like Disease.Anergy induction by dimeric TCR ligandsExpression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic proteinpH-dependent peptide binding properties of the type I diabetes-associated I-Ag7 molecule: rapid release of CLIP at an endosomal pH.A triad of molecular regions contribute to the formation of two distinct MHC class II conformers.HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patientsAnalysis, Isolation, and Activation of Antigen-Specific CD4(+) and CD8(+) T Cells by Soluble MHC-Peptide Complexes.Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR.Definition of APC presentation of phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate to Vgamma2Vdelta 2 TCR.Dimeric MHC-peptides inserted into an immunoglobulin scaffold as new immunotherapeutic agents.Analysis of interactions in a tapasin/class I complex provides a mechanism for peptide selection.Interactions of soluble recombinant integrin alphav beta5 with human adenoviruses.Extraordinary cross-reactivity of an autoimmune T-cell receptor recognizing specific peptides both on autologous and on allogeneic HLA class II molecules.Detailed analysis of the effects of Glu/Lys beta69 human leukocyte antigen-DP polymorphism on peptide-binding specificity.Analysis of heterophilic and homophilic interactions of cadherins using the c-Jun/c-Fos dimerization domains.Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-gliadin.A cell-based high-throughput screening assay system for inhibitor compounds of antigen presentation by HLA class II moleculeFunctional recombinant MHC class II molecules and high-throughput peptide-binding assays.The HLA-DP2 protein binds the immunodominant epitope from myelin basic protein, MBP85-99, with high affinity.Unraveling the structural basis for the unusually rich association of human leukocyte antigen DQ2.5 with class-II-associated invariant chain peptides.Preparation and crystal structure of the recombinant α1/α2 catalytic heterodimer of bovine brain platelet-activating factor acetylhydrolase Ib
P2860
Q24534881-F265AA66-B9C5-4195-8C1B-8FF60030A0B0Q24633885-C6AE82E0-6B0A-4699-ADE3-C7A0FBA2A171Q26799836-293DE7C8-5E0A-47D0-8AC1-A7CBD46BD985Q27480953-F77222B4-32B0-491D-9F3B-30EEA6E900CAQ27643106-F0F1305F-DDD7-43BC-BAE6-66ED613A02D1Q27765717-44A42777-214A-49A8-8345-3F4F425AC29EQ33630225-2CDBD468-A3C3-4501-94F9-3E3F8AC3E0EDQ34550189-3C946865-1201-4D14-9AF2-16D1CE1174C8Q34792611-81C37BD4-CF8C-4B30-90A4-F18CF5B4B5EEQ35177057-2F7F7156-E488-4047-8C1A-58D7422FDC85Q35721897-5D97CFFE-20C5-4156-911C-1CAC3CB599BCQ36149336-713CCE27-BCB0-4E87-9ED3-13C2766297DCQ36322630-CB19143B-82A6-4BF6-8451-BF4B4D85F80CQ36368211-1BBEF32C-089F-463D-8B54-D87DA3753398Q36984434-6ED67587-AA73-4DAC-AD11-2A7FD06AB097Q37028039-4C09A09F-8546-42BC-85ED-6CDA3020940FQ37054621-F8885E7E-C428-4002-96C3-3C185C4A95F4Q37323197-4EF47FC5-8D65-466F-993C-7B0036E015A4Q37344573-2566A4CE-8228-4B73-B270-46C3CF8B7338Q37857379-2E5CC742-A025-44AC-8F87-9A8FC071E95CQ38304154-0964854D-9601-43EF-BAD3-8C9D3091CA74Q38332663-A14C144E-90B9-419A-AE51-85F35BDEE639Q40121895-84964E81-8CD9-4C95-B3D2-9DC20385EF76Q40616521-972AE660-F128-420D-A4C1-BE372F3A1989Q40742966-0E66B15B-AEB0-4D3E-89F4-8BDF689DB7FCQ41131780-70AC46A9-4D31-48DA-95A3-A7BE66EF8870Q41782459-AE5DFA44-6449-4019-8148-E989E03F426CQ43118417-779FF4AE-1A72-4F9B-A76A-FE5A4DB3B356Q44820406-EA490201-6932-490A-B662-C93F61E91EE3Q51079315-59DC2AAC-6C9D-442B-A8C8-3E8CD15CFB49Q56016554-C85417D9-5C06-4D32-8233-E63E1BA5B6EE
P2860
Expression of recombinant HLA-DR2 molecules. Replacement of the hydrophobic transmembrane region by a leucine zipper dimerization motif allows the assembly and secretion of soluble DR alpha beta heterodimers.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Expression of recombinant HLA- ...... le DR alpha beta heterodimers.
@en
Expression of recombinant HLA- ...... le DR alpha beta heterodimers.
@nl
type
label
Expression of recombinant HLA- ...... le DR alpha beta heterodimers.
@en
Expression of recombinant HLA- ...... le DR alpha beta heterodimers.
@nl
prefLabel
Expression of recombinant HLA- ...... le DR alpha beta heterodimers.
@en
Expression of recombinant HLA- ...... le DR alpha beta heterodimers.
@nl
P2093
P2860
P356
P1476
Expression of recombinant HLA- ...... le DR alpha beta heterodimers.
@en
P2093
Foncerrada L
Kalandadze A
Wucherpfennig KW
P2860
P304
20156-20162
P356
10.1074/JBC.271.33.20156
P407
P577
1996-08-01T00:00:00Z